Related Articles
Complete response to azacitidine priming and nab‑paclitaxel in non‑Hodgkin lymphoma resistant to biochemotherapy
Diffuse large B-cell lymphoma: 10 years' real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone
Long-term follow-up of localized, primary gastric diffuse large B-cell lymphoma treated with rituximab and CHOP
Reassessment of the prognostic value of the International Prognostic Index and the revised International Prognostic Index in patients with diffuse large B-cell lymphoma: A multicentre study
Phase 2 study of CHOP‑R‑14 followed by 90Y‑ibritumomab tiuxetan in patients with previously untreated diffuse large B‑cell lymphoma